scholarly journals THE RESPONSE OF NORMAL INDIVIDUALS AND PATIENTS WITH DIABETES INSIPIDUS TO THE INGESTION OF WATER 1

1937 ◽  
Vol 16 (2) ◽  
pp. 197-202 ◽  
Author(s):  
Thomas Findley ◽  
H. L. White
1988 ◽  
Vol 27 (7) ◽  
pp. 330-332 ◽  
Author(s):  
Eileen Doherty-Fuller ◽  
Kenneth C. Copeland

1971 ◽  
Vol 40 (6) ◽  
pp. 497-511 ◽  
Author(s):  
A. F. Lant ◽  
G. M. Wilson

1. The antidiuretic effects of oral therapy with benzothiadiazine and phthalimidine diuretics have been studied in seven patients with diabetes insipidus of pituitary origin. 2. The immediate and chronic phases of diuretic-induced antidiuresis differ in their characteristics. Immediate antidiuresis is closely related both to the saluretic action of the diuretics and to the level of fluid turnover prevailing before their administration. By contrast, the findings in four patients maintained on polythiazide or clorexolone for at least 4 years show that antidiuresis persists at a time when saluretic effects have ceased and there is no longer any detectable disturbance in body sodium metabolism. A change in mechanism of antidiuresis appears to occur with the passage of time. 3. There is a parallelism between the characteristics of the chronic antidiuretic and antihypertensive actions of diuretics. The mechanism of both effects remains obscure. 4. Despite uncertainty as to mechanism, diuretic therapy offers a reliable means of treating diabetes insipidus on a long-term basis. The only complication encountered was symptomless hypokalaemia which developed despite regular use of supplemental oral potassium. Combined administration of triamterene or amiloride with either polythiazide or clorexolone has been used with success as an alternative regime.


The Lancet ◽  
1968 ◽  
Vol 291 (7549) ◽  
pp. 948-952 ◽  
Author(s):  
I. Vávra ◽  
A. Machová ◽  
V. Holecek ◽  
J.H. Cort ◽  
M. Zaoral ◽  
...  

2009 ◽  
Vol 2009 ◽  
pp. 1-4 ◽  
Author(s):  
Joanna Rosalind Cunnington ◽  
Ramesh Jois ◽  
Ivan Zammit ◽  
David Scott ◽  
John Isaacs

Wegener's granulomatosis of the pituitary gland resulting in diabetes insipidus is a rare complication of the disease. Standard treatment for Wegener's granulomatosis involves a combination of prednisolone and cylophosphamide, however biologic agents are now being used in refractory cases. We report three cases of patients with diabetes insipidus as a complication of Wegener's granulomatosis who were treated with biologic agents. All three cases showed clinical response to treatment with biologic agents including rituximab and alemtuzumab and two cases demonstrated improvement in pituitary gland abnormalities by MRI. Clinicians should be aware that diabetes insipidus can present as a complication of Wegener's granulomatosis and that biologic therapies may be effective in refractory cases.


Sign in / Sign up

Export Citation Format

Share Document